X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (59334) 59334
Newspaper Article (1784) 1784
Newsletter (653) 653
Magazine Article (617) 617
Book Chapter (151) 151
Book / eBook (82) 82
Web Resource (52) 52
Transcript (49) 49
Trade Publication Article (47) 47
Publication (38) 38
Conference Proceeding (22) 22
Dissertation (20) 20
Book Review (14) 14
Reference (3) 3
Paper (2) 2
Streaming Video (2) 2
Government Document (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (51567) 51567
anticoagulants - therapeutic use (38722) 38722
female (23952) 23952
male (23140) 23140
anticoagulants (21408) 21408
middle aged (16486) 16486
aged (15859) 15859
adult (11937) 11937
risk factors (10006) 10006
anticoagulants - adverse effects (9692) 9692
warfarin (8937) 8937
treatment outcome (8755) 8755
anticoagulants - administration & dosage (7849) 7849
hematology (7345) 7345
thrombosis (7119) 7119
cardiac & cardiovascular systems (7099) 7099
peripheral vascular disease (6997) 6997
warfarin - therapeutic use (6809) 6809
heparin - therapeutic use (6422) 6422
stroke (6271) 6271
thromboembolism (6190) 6190
aged, 80 and over (6185) 6185
atrial fibrillation (5698) 5698
prevention (5459) 5459
medicine, general & internal (5330) 5330
surgery (5312) 5312
retrospective studies (5090) 5090
anticoagulation (4841) 4841
risk (4796) 4796
atrial fibrillation - drug therapy (4603) 4603
heparin (4536) 4536
therapy (4433) 4433
venous thromboembolism (4396) 4396
pharmacology & pharmacy (4359) 4359
management (4295) 4295
platelet aggregation inhibitors - therapeutic use (4259) 4259
care and treatment (4250) 4250
administration, oral (4173) 4173
time factors (4076) 4076
animals (4000) 4000
hemorrhage - chemically induced (3910) 3910
fibrinolytic agents - therapeutic use (3758) 3758
patients (3743) 3743
stroke - prevention & control (3699) 3699
mortality (3679) 3679
drug therapy (3671) 3671
atrial fibrillation - complications (3583) 3583
thromboembolism - prevention & control (3554) 3554
medicine & public health (3473) 3473
abridged index medicus (3395) 3395
analysis (3376) 3376
prospective studies (3352) 3352
heparin, low-molecular-weight - therapeutic use (3290) 3290
follow-up studies (3231) 3231
molecular-weight heparin (3208) 3208
health aspects (3164) 3164
adolescent (3016) 3016
risk assessment (2980) 2980
international normalized ratio (2969) 2969
anticoagulants - pharmacology (2945) 2945
research (2927) 2927
aspirin (2913) 2913
aspirin - therapeutic use (2890) 2890
dabigatran (2885) 2885
pregnancy (2766) 2766
rivaroxaban (2737) 2737
warfarin - adverse effects (2669) 2669
cardiology (2662) 2662
recurrence (2540) 2540
venous thrombosis - drug therapy (2493) 2493
cardiac arrhythmia (2487) 2487
stroke - etiology (2486) 2486
hemorrhage (2481) 2481
deep-vein thrombosis (2450) 2450
atrial-fibrillation (2411) 2411
heparin - adverse effects (2325) 2325
blood coagulation - drug effects (2309) 2309
incidence (2247) 2247
warfarin - administration & dosage (2246) 2246
diagnosis (2227) 2227
bleeding (2225) 2225
thrombosis - prevention & control (2220) 2220
thrombosis - drug therapy (2210) 2210
prognosis (2155) 2155
complications (2147) 2147
drug therapy, combination (2134) 2134
clinical neurology (2120) 2120
pulmonary embolism (2112) 2112
venous thrombosis (2066) 2066
venous thromboembolism - prevention & control (2046) 2046
internal medicine (2042) 2042
risk-factors (2028) 2028
thrombin (1999) 1999
dosage and administration (1983) 1983
thrombosis - etiology (1951) 1951
randomized controlled trials as topic (1938) 1938
safety (1936) 1936
clinical trials (1888) 1888
coagulation (1856) 1856
medical research (1849) 1849
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (41) 41
Gerstein Science - Stacks (30) 30
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (4) 4
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Mt Sinai Hospital - Online (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Online (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (54917) 54917
German (2254) 2254
French (1948) 1948
Spanish (886) 886
Russian (748) 748
Italian (560) 560
Japanese (497) 497
Chinese (204) 204
Polish (200) 200
Dutch (199) 199
Portuguese (141) 141
Danish (104) 104
Hungarian (93) 93
Swedish (93) 93
Czech (91) 91
Norwegian (68) 68
Romanian (66) 66
Finnish (63) 63
Hebrew (61) 61
Turkish (50) 50
Bulgarian (41) 41
Croatian (32) 32
Serbian (30) 30
Ukrainian (30) 30
Korean (15) 15
Lithuanian (15) 15
Slovak (13) 13
Icelandic (5) 5
Bosnian (3) 3
Arabic (2) 2
Persian (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Thrombosis and Haemostasis, ISSN 0340-6245, 09/2015, Volume 113, Issue 5, pp. 931 - 942
Summary Several new anticoagulants have entered the clinical arena or are under clinical development. These drugs include indirect (fondaparinux) and direct... 
Review Article | Rivaroxaban | Antidotes | Dabigatran | New anticoagulants | Apixaban | ANDEXANET-ALPHA | VITAMIN-K ANTAGONISTS | rivaroxaban | apixaban | ATRIAL-FIBRILLATION | antidotes | IN-VITRO | ANTIIDIOTYPIC ANTIBODIES | PROTHROMBIN COMPLEX CONCENTRATE | ORAL ANTICOAGULANTS | MOLECULAR-WEIGHT HEPARIN | dabigatran | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | HEMATOLOGY | ACUTE VENOUS THROMBOEMBOLISM | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Anticoagulants - administration & dosage | Thrombosis - complications | Humans | Antibodies, Monoclonal - therapeutic use | Heparin - therapeutic use | Hemorrhage - prevention & control | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Vitamin K - antagonists & inhibitors | Benzamides - therapeutic use | Anticoagulants - chemistry | Factor Xa - therapeutic use | Intracranial Hemorrhages - prevention & control | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Hemostatics - chemistry | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Infusions, Parenteral | Clinical Trials as Topic | Factor Xa Inhibitors - therapeutic use | Animals | Protamines - therapeutic use | Pyridones - therapeutic use | Thrombosis - drug therapy | Hemorrhage - chemically induced | Hemostatics - therapeutic use
Journal Article
Postgraduate Medical Journal, ISSN 0032-5473, 12/2016, Volume 92, Issue 1094, pp. 726 - 734
An estimated 5.1 million Americans have chronic heart failure and this is expected to increase 25% by 2030. Heart failure is a clinical syndrome that evolves... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | METAANALYSIS | RANDOMIZED-TRIAL | IN-HOSPITAL MORTALITY | DYSFUNCTION | NATRIURETIC PEPTIDE | COMBINATION | EPIDEMIOLOGY | ROSUVASTATIN | URODILATIN | Vasodilator Agents - therapeutic use | Erythropoietin - therapeutic use | United States | Humans | Calcium Channel Blockers - therapeutic use | Heart Failure - physiopathology | Aminobutyrates - therapeutic use | Cardiotonic Agents - therapeutic use | Societies, Medical | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Isosorbide Dinitrate - therapeutic use | Cardiology | Platelet Aggregation Inhibitors - therapeutic use | Digoxin - therapeutic use | Adrenergic beta-Antagonists - therapeutic use | Hematinics - therapeutic use | Fumarates - therapeutic use | Anticoagulants - therapeutic use | Amides - therapeutic use | Antihypertensive Agents - therapeutic use | Evidence-Based Medicine | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | American Heart Association | Stroke Volume | Cardiovascular Agents - therapeutic use | Hydralazine - therapeutic use | Atrial Natriuretic Factor - therapeutic use | Iron - therapeutic use | Benzazepines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Diuretics - therapeutic use | Tetrazoles - therapeutic use | Peptide Fragments - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Drug Combinations | Practice Guidelines as Topic | Heart failure | Care and treatment | Usage | Analysis | Americans | Diagnosis | Cardiac output | Health aspects | Evidence-based medicine
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
Vitamin K antagonists are commonly used by clinicians to provide anticoagulation to patients who have or are at risk of having thrombotic events. In addition... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
.... Anticoagulation uses 1 of 4 choices: bivalirudin, unfractionated heparin, enoxaparin, and fondaparinux... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Journal Article
Journal Article
Journal Article